NCT01810913 2026-04-15
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
Clinical Trials
10 trialsNCT04402788 2026-04-15
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT05691478 2026-04-15
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT05987241 2026-04-15
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06203600 2026-04-15
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT04628767 2026-04-14
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT04333537 2026-04-03
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NRG Oncology
Phase 2/3 Recruiting
NCT07001748 2026-03-23
STOPGAP II
Eastern Cooperative Oncology Group
Phase 2/3 Recruiting
NCT06616584 2026-01-23
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Recruiting
NCT06537154 2025-07-30
NEO-BLAST
University of British Columbia
Phase 2/3 Recruiting